A -- RESEARCH & DEVELOPMENT -- THE VA HAS IDENTIFIED AND USED AN ANTAGONIST TO INHIBIT THE EFFECTS OF ALCOHOL ON CELL-TO-CELL ADHESION MEDIATED BY THE IMMUNOGLOBULIN (LG) CELL-ADHESION MOLECULE CALLED L1.

Notice Date

September 24, 2001

Contracting Office

National Technology Transfer Center, Wheeling Jesuit University, 316 Washington Ave., Wheeling, WV 26003-6295

ZIP Code

26003-6295

Solicitation Number

#00-029

Response Due

November 1, 2001

Point of Contact

Mr. William Chard at 1-800-678-6882 or (304) 243-2039

E-Mail Address

Click here to contact the contracting officer via (wchard@nttc.edu)

Description

The Department of Veterans Affairs (VA), through the National Technology Transfer Center (NTTC), is seeking a commercial partner to license and/or further develop this technology through a Cooperative Research and Development Agreement (CRADA) in order to expedite bringing the technology to market. -- -The VA has identified and used an antagonist to inhibit the effects of alcohol on cell-to-cell adhesion mediated by the immunoglobulin (lg) cell-adhesion molecule called L1. The L1 protein plays a critical role in axonal guidance, neurite extension, synaptogensis and myelination. Brian lesions in children with mutations in the gene for L1 resemble those of children with fetal alcohol syndrome. Moreover, an antagonist of ethanol effects on L1 prevents ethanol cell death and dysmorphology in mouse whole embryo culture. This technology is preliminary and has not yet progressed to in-vivo testing. The VA filed a US patent on 2/27/01. -- - Any company interested in discussing this technology with the VA should contact the NTTC for more information by calling Mr. William Chard at 1-800-678-6882 or (304) 243-2039 or by e-mail at: wchard@nttc.edu

Record

Loren Data Corp. 20010926/ASOL004.HTM (W-267 SN50Y538)